Vactosertib

Overview

Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 ( ALK5 ) inhibitor with an IC 50 of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 ( IC 50 of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-19928
• CAS No.: 1352608-82-2
• Molecular Formula: C22H18FN7
• Molecular Weight: 399.42
• Purity: 99.53%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (6.26 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source